News Release - Eli Lilly and Company
WEBMay 13, 2022 · FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 …
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
WEB7 hours ago · “The entities currently mass-producing and mass-marketing compounded and counterfeit tirzepatide need to stop immediately,” Eli Lilly, the maker of Zepbound and Mounjaro, said in an emailed ...
News Release - Eli Lilly and Company
WEBJun 20, 2024 · Mounjaro ® and Zepbound ® are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss. Lilly does not promote or encourage use of Mounjaro ®, Zepbound ®, or any Lilly medicine outside of its FDA-approved indication.
Drugmaker Lilly slates another $4.5B for manufacturing and drug ...
WEB1 day ago · Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve manufacturing. The company said in May that it also was expanding there to make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.. Those drugs have funneled fresh revenue to Lilly and prompted the company in August to push its annual forecast ...
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity ... - CNN
WEBNov 8, 2023 · The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes...
Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
WEBAug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
NHS to Offer Eli Lilly Weight-Loss Drug Mounjaro to Some …
WEB23 hours ago · Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug. Patients most in need ...
News Release - Eli Lilly and Company
WEBMounjaro led to significantly greater fat mass reductions compared to placebo and to injectable semaglutide 1 mg in adults with type 2 diabetes in mechanism of action study. Exploratory analysis showed that Mounjaro achieved A1C and weight targets in less time than injectable semaglutide 1 mg or titrated insulin degludec.
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit ...
WEBApr 30, 2024 · Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up …
Eli Lilly lifts guidance after sales of Mounjaro and Zepbound …
WEBApr 30, 2024 · Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted the US pharmaceutical group to lift its guidance for the year and pushed its share...